Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T cell and interferon expression in tonsils after sublingual immunotherapy and nasal live attenuated influenza vaccine
2013-000492-32Phase 4Completed
- Sponsor
- Turku University Hospital
- Start
- Jun 2013
- Modality
- Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4 trial of Oralair, allergenic extract of birch and live attenuated influenza vaccine in allergic rhinitis (AR), Birch Pollen Allergic Rhinitis (BPAR) and influenza (5 arms), sponsored by Turku University Hospital. Primary endpoint: Tonsillectomy completion. Started Jun 2013; status: completed.
02
Drugs
Oralairallergenic extract of birchlive attenuated influenza vaccine
03
Conditions
allergic rhinitis (AR)Birch Pollen Allergic Rhinitis (BPAR)influenza
Beyond the preview
Go deeper on 2013-000492-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000492-32.